Ranked by interpretable importance, issuer history, magnitude, and accounting profile. No directional recommendation.
Capital expenditure changed +2546.5% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes. Relative percentage is de-emphasized because the comparison has a low base. This reverses 4 consecutive comparable moves in the opposite direction.
Working capital / assets changed +2253 basis points from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Current ratio changed +203.3% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Operating margin changed -305757 basis points from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
Current liabilities changed +42.1% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
Operating income changed -48.3% from the comparable as-filed period.
Revenue changed +27.9% from the comparable as-filed period.
Stock-based compensation changed +62.3% from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
Gross margin changed +1352 basis points from the comparable as-filed period.
Capex / revenue changed +310299 basis points from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
Net income changed -33.2% from the comparable as-filed period.
Cash & equivalents changed +113.5% from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes.
SBC / revenue changed +115508 basis points from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
Shares outstanding changed +19.1% from the comparable as-filed period. The change ranks at the 75th percentile of 8 prior comparable changes.
Research & development changed +48.0% from the comparable as-filed period.
Trade receivables changed +50.0% from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes.
Stockholders' equity changed +261.5% from the comparable as-filed period.
Cost of revenue changed -100.0% from the comparable as-filed period.
Free-cash-flow margin changed -615354 basis points from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
Operating cash-flow margin changed -305055 basis points from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
R&D / revenue changed +160500 basis points from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
Method Importance combines metric-family relevance, magnitude, issuer-history unusualness, persistence, and financial-statement significance. It is analytical prioritization, not a legal materiality conclusion or investment signal.